# Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-menopausal Women With Female Sexual Arousal Disorder

> **NCT00640458** · PHASE2 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 20 (actual)

## Conditions studied

- Female Sexual Arousal Disorder

## Interventions

- **DRUG:** Sildenafil 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00640458
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00640458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00640458, "Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-menopausal Women With Female Sexual Arousal Disorder". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00640458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*